Werewolf Therapeutics Inc
NASDAQ:HOWL
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.64
7.91
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Werewolf Therapeutics Inc
Operating Margin
Werewolf Therapeutics Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | US |
| Market Cap | 85.3m USD |
| Operating Margin |
-1 955%
|
| Country | FR |
| Market Cap | 6T USD |
| Operating Margin |
-17 527%
|
| Country | US |
| Market Cap | 314.7B USD |
| Operating Margin |
28%
|
| Country | US |
| Market Cap | 147.4B USD |
| Operating Margin |
19%
|
| Country | US |
| Market Cap | 119.4B USD |
| Operating Margin |
40%
|
| Country | US |
| Market Cap | 113.8B USD |
| Operating Margin |
38%
|
| Country | US |
| Market Cap | 94.1B EUR |
| Operating Margin |
-370%
|
| Country | AU |
| Market Cap | 135.4B AUD |
| Operating Margin |
26%
|
| Country | US |
| Market Cap | 82.6B USD |
| Operating Margin |
30%
|
| Country | US |
| Market Cap | 39.3B EUR |
| Operating Margin |
-33%
|
| Country | NL |
| Market Cap | 34.3B EUR |
| Operating Margin |
-22%
|
Werewolf Therapeutics Inc
Glance View
Werewolf Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2021-04-30. The firm is focused on developing a pipeline of cancer treatments. The company is developing immuno-stimulatory therapeutics designed to act selectively within the tumor microenvironment to enhance the body’s immune response to cancer. Its PREDATOR platform is designed to conditionally activate molecules that stimulate both adaptive and innate immunity while addressing the limitations of conventional proinflammatory immune therapies. The INDUKINETM molecules, are intended to selectively target the tumor microenvironment (TME). PREDATOR platform consists of protein engineering technologies which are used to generate INDUKINE molecules with multiple functional domains rationally engineered into a single protein to achieve the pharmaceutical profile. The firm using PREDATOR platform, has developed three initial product candidates: WTX-124, WTX-330 and WTX-613.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Werewolf Therapeutics Inc's most recent financial statements, the company has Operating Margin of -1 955.4%.
You don't have any saved screeners yet
